Zevra Therapeutics, Inc.

Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

SAN DIEGO – Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Zevra Therapeutics, Inc. (NASDAQ: ZVRA). The investigation focuses on Zevra’s executive officers and whether investor losses may be recovered under federal securities laws.

What if I purchased Zevra securities?

Name

This field is for validation purposes and should be left unchanged.

If you suffered a loss on your investment and would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. The information provided will be held in strict confidence unless and until you authorize us to disclose it.

Name(Required)

First Last

Email(Required)

Phone(Required)

Estimated Losses(Required)

Where did you see our press release?(Required)

If you selected 'Other' above, please specify below:(Required)

Would you like to receive future case and securities updates from Johnson Fistel, PLLP via email?(Required)

Yes

Would you like to receive information about Johnson Fistel, PLLP's free portfolio monitoring service?(Required)

Yes

By checking the box, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Johnson Fistel, PLLP, and that submission to or receipt of information from the firm or one of its attorneys via this form, website, email, or telephone does not create an attorney-client relationship.(Required)

I Agree

Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471.
There is no cost or obligation to you.

Background of the investigation

On August 12, 2025, Zevra disclosed its second-quarter 2025 financial results and reported, among other things, an $11.7 million inventory write-down. Following this disclosure, Zevra’s share price declined by approximately 25%.

On November 20, 2025, Zevra announced the resignation of its Chief Financial Officer. Following this announcement, Zevra’s stock price declined approximately 18% over the following trading days.

In light of these disclosures, Johnson Fistel is investigating whether Zevra complied with the federal securities laws. If you suffered losses from your investment in Zevra stock, contact Johnson Fistel.

Zevra Therapeutics, Inc.

Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

California

New York

Georgia

Colorado

Idaho